Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eton Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eton Pharmaceuticals's regulatory disclosures and financial reporting.
Eton Pharmaceuticals, Inc. (ETON) director Paul V. Maier reported multiple transactions on 2026-08-28. He exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share and 12,500 shares at $7.31 per share, receiving common stock.
On the same date, he sold an aggregate of 50,000 common shares in open-market transactions: 36,387 shares at a weighted average price of $58.64 (range $58.50–$58.97), 13,485 shares at $60.21 (range $60.00–$61.00), and 128 shares at $61.77 (range $61.10–$61.98).
Eton Pharmaceuticals, Inc. (ETON) director Paul V. Maier exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share and concurrently sold 50,000 shares of common stock on 2026-08-28 in multiple open-market transactions at weighted-average prices between about $58.50 and $61.98 per share. Following the option exercise, the reported option position was reduced to zero.
Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock that Paul W. Maier, identified as a director, plans to sell under Rule 144. The notice covers a proposed sale of 50,000 shares of common stock, expected to be sold through Raymond James & Associates, Inc. on or about 08/28/2026. The shares are to be sold for the account of Paul W. Maier and are indicated as relating to stock options.
Eton Pharmaceuticals, Inc. (ETON) reported insider equity activity by Chief Business Officer David Krempa. On 2026-08-24 he exercised an Employee Stock Option to acquire 25,000 shares of common stock at an exercise price of $7.31 per share, reducing that option position to 70,000 options remaining. The resulting 25,000 common shares were then sold in market transactions at a weighted average price of $65.07 per share, with individual sale prices ranging from $64.88 to $65.57. The option originally granted on 2019-02-20 vested in 48 equal monthly installments and expires on 2029-02-19. The filing indicates these transactions were not made pursuant to a Rule 10b5-1 trading plan.
Eton Pharmaceuticals, Inc. (ETON) has an affiliated officer, David Krempa, filing a Rule 144 notice to sell up to 25,000 shares of common stock through Raymond James & Associates, Inc. The planned sale on 08/24/2026 is tied to a stock option exercise for cash.
During the prior three months, Krempa reported sales of 37,524 shares of Eton common stock on 05/26/2026 for $1,180,201.00 and 19,679 shares on 05/27/2026 for $618,569.00. The shares are listed on Nasdaq, and Raymond James is identified as the broker handling the proposed transaction.
Eton Pharmaceuticals, Inc. (ETON) reported that President & CEO Sean Brynjelsen sold a total of 100,000 shares of common stock in four open-market transactions on August 19–20, 2026. The sales used weighted average prices of $62.65, $62.12, $61.11, and $60.17 per share, each executed in multiple trades within stated price ranges.
Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock that Sean E. Brynjelsen plans to sell under Rule 144. The notice lists a proposed sale of 100,000 common shares through Raymond James & Associates and discloses that 120,000 shares of common stock were sold on 05/28/2026 for about $3,826,015.00. The securities to be sold trace back to 1,000,000 founder shares acquired on 05/17/2017.
Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock for which Sean E. Brynjelsen has filed a notice to sell shares under Rule 144. The notice covers 100,000 shares of common stock to be sold through Raymond James & Associates, Inc., with an aggregate market value of $6,343,000.00 and 28,583,135 shares of this class outstanding as of the notice. The shares are described as Founder Shares acquired from the issuer on 05/17/2017 by grant, and are listed on Nasdaq. No shares are reported as sold during the past three months.
Eton Pharmaceuticals, Inc. reported strong growth for the quarter and six months ended June 30, 2026. Quarterly net revenues were $37,589 (thousands), up from $18,928, driven mainly by higher sales of INCRELEX®, GALZIN®, Carglumic Acid and the addition of HEMANGEOL®.
Gross profit for the quarter rose to $25,413 from $11,924, and Eton moved from a net loss of $(2,585) to net income of $11,578. For the first half of 2026, revenues increased to $61,855 from $36,210, with net income of $13,132 versus a loss of $(4,157) a year earlier. Adjusted EBITDA for the six months improved to $21,944 from $6,726.
The company ended June 30, 2026 with $26,845 in cash and cash equivalents, total assets of $115,807, and working capital of $23,500 (thousands). It invested $14,000 to acquire U.S. commercial rights to HEMANGEOL® and $1,000 for an ultra-rare disease product candidate, and expanded its rare disease portfolio while carrying $27,903 of net debt under its SWK credit facility. Revenues and receivables remain highly concentrated with specialty pharmacy customer AnovoRx.
Eton Pharmaceuticals reported very strong results for the quarter ended June 30, 2026. Net revenue was $37.6 million, up 99% from $18.9 million a year earlier, driven by the HEMANGEOL relaunch and growth across the rare disease portfolio, including INCRELEX, ALKINDI SPRINKLE, GALZIN and Carglumic Acid. Gross profit rose to $25.4 million, while adjusted gross profit reached $27.4 million with a 73% margin.
Operating leverage improved markedly: EBITDA was $14.1 million versus a small loss a year ago, and Adjusted EBITDA was $16.2 million, or 43% of revenue. GAAP net income was $11.6 million (diluted EPS $0.35), compared with a $2.6 million loss (−$0.10 per share) in the prior-year quarter; non-GAAP net income was $14.3 million (diluted EPS $0.43). Cash and equivalents were $26.8 million at quarter end.
The company raised 2026 guidance and now expects revenue above $145 million and an Adjusted EBITDA margin of at least 35%, both higher than prior targets. Management highlighted successful HEMANGEOL patient transition, the ASN-001 licensing, the planned AMGLIDIA NDA by end-2026, the IMPAVIDO launch expected in September 2026, and multiple ongoing label and development studies across its rare disease pipeline.